Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
– In ECOSPOR lll, Seres’ lead therapeutic candidate incorporated itself rapidly and durably into the microbiome to prevent C. difficile infection recurrence – – Within one week of treatment, SER-109 ...